Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552948 | 0.86 | TSHR (0.50) | TSHRALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL8005039 | 0.85 | LMNA (0.50) | TSHRBLMKDM6BKDM5CEGLN1 | |
| SCHEMBL1048350 | 0.83 | — | — | |
| SCHEMBL27784079 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL27999865 | 0.81 | — | — | |
| SCHEMBL28034378 | 0.81 | — | — | |
| SCHEMBL7790150 | 0.81 | — | — | |
| SCHEMBL5803777 | 0.81 | — | — | |
| SCHEMBL11671066 | 0.78 | — | — | |
| SCHEMBL2231528 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108219666-A | Counter infrared ray, antibacterial, weatherability Water-based ceramic-imitating coating and preparation method thereof | 段宝荣 | 2018-06-29 | — | — | CN | claimed |
| CN-108219666-A | Counter infrared ray, antibacterial, weatherability Water-based ceramic-imitating coating and preparation method thereof | 段宝荣 | 2018-06-29 | — | — | CN | disclosed |
| CN-103788070-B | The inhibitor class polymers of DPP 4 | 南京华威医药科技开发有限公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-103788070-A | DPP-4 inhibitor polymer | NANJING HUAWE MEDICAL TECHNOLOGY DEV CO LTD | 2014-05-14 | — | — | CN | disclosed |
| EP-2101772-B1 | INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF | CORNELL RES FOUNDATION INC (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8148398-B2 | Nondepolarizing benzyltetrahydroisoquinoline based relaxants; safer, reduced side effects; kits for intravenous injection and reversing effects | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2101772-A1 | INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF | Cornell Research Foundation, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080139482-A1 | INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF | CORNELL RESEARCH FOUNDATION, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008070121-A1 | INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| CN-1012732-B | GEN-DIHALO-1, 8-DIAMINO-4-AZA-OCTANES | MERRELL DOW PHARMA (US) | 1991-06-05 | — | — | CN | disclosed |
| CN-86105154-A | Together with-dihalo-1, the preparation method of 8-diamino-4-azepine-octane | — | 1987-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139482-A1 | INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF | CHRNB4, NMBR, CHRNA5 | TSHR 805/4885ADRA2A 334/4885ADRA1A 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.